Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy
in the Induction Therapy for Ph-Negative Acute Lymphoblastic
Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell
Trial

a 2022

Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK et. al.

Basic information

Original name

Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

Authors

SALEK, Cyril, František FOLBER (203 Czech Republic, belonging to the institution), Štěpán HRABOVSKÝ (203 Czech Republic, belonging to the institution), Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA and Michael DOUBEK

Edition

2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

BLINA-CELL

RIV identification code

RIV/00216224:14110/22:00133021

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1182/blood-2022-157361

UT WoS

000893223203131

Keywords (in Czech)

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Keywords in English

blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia

Abstract

V originále

Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA and Michael DOUBEK. Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial. 2022. Available from: https://dx.doi.org/10.1182/blood-2022-157361.

@proceedings{2361066,
   author = {Salek, Cyril and Folber, František and Hrabovský, Štěpán and Koristek, Zdenek and Horacek, Jan M and Fronkova, Eva and Soukup, Petr and Benkova, Katerina and Cetkovsky, Petr and Trka, Jan and Doubek, Michael},
   doi = {http://dx.doi.org/10.1182/blood-2022-157361},
   keywords = {blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia},
   language = {eng},
   title = {Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial},
   url = {https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose},
   year = {2022}
}

TY  - CONF
ID  - 2361066
AU  - Salek, Cyril - Folber, František - Hrabovský, Štěpán - Koristek, Zdenek - Horacek, Jan M - Fronkova, Eva - Soukup, Petr - Benkova, Katerina - Cetkovsky, Petr - Trka, Jan - Doubek, Michael
PY  - 2022
TI  - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
KW  - blinatumomab
KW  - high-dose chemotherapy
KW  - acute lymphoblastic leukemia
UR  - https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose
N2  - Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.
ER  -

SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA and Michael DOUBEK. \textit{Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial}. 2022. Available from: https://dx.doi.org/10.1182/blood-2022-157361.

Detailed Information on Publication Record